DOD Orthotics and Prosthetics Outcomes, Clinical Trial Award | W81XWH 21 OPORP CTA

Opportunity Information: Apply for W81XWH 21 OPORP CTA

The DOD Orthotics and Prosthetics Outcomes, Clinical Trial Award (FY21 OPORP CTA) is a Department of Defense funding opportunity run through the U.S. Army Medical Research Acquisition Activity (USAMRAA) that focuses on supporting clinical trials designed to measurably improve outcomes for people with limb loss or limb impairment. The target beneficiaries include Service Members and military beneficiaries, Veterans, and related civilian populations, with an emphasis on generating evidence that can directly inform real-world clinical care and decision-making.

At its core, this program is meant to fund clinical trials that evaluate orthoses and prostheses using patient-centric outcomes, meaning the endpoints should reflect what matters to patients in daily life and health (for example, functional performance, mobility, comfort, quality of life, pain, participation, safety, and other clinically meaningful measures). The intent is not simply to build or refine devices in a lab, but to produce clinically useful evidence that can enhance, optimize, and potentially standardize care. Projects can span a wide range, from smaller proof-of-concept studies that test feasibility and help shape later trials, to large trials in relevant patient populations that can provide strong, practice-changing conclusions.

The program explicitly encourages trial designs that improve the chances of adoption in routine care settings. In addition to traditional randomized controlled trials, the solicitation highlights alternate clinical research designs such as pragmatic trials and practice-based evidence studies. These approaches are valued because they can better reflect how orthotic and prosthetic devices perform in real clinical environments, across diverse patients, clinicians, and settings, and because they can generate evidence that is useful not only for clinicians but also for policy and coverage decisions.

Another priority area is multidisciplinary work aimed at reducing or preventing secondary injuries that can occur with limb loss or limb impairment, such as overuse injuries, falls, skin breakdown, musculoskeletal strain, or other downstream complications. The program will consider studies that include rehabilitation strategies, but it requires a clear justification showing how the rehabilitation component is expected to improve outcomes specifically related to the orthotic or prosthetic device compared with standard of care. In other words, rehabilitation cannot be included as a general add-on; it needs to be tied to improved device-related outcomes.

Applicants must choose one of two funding levels, and only one category can be selected per application. Funding Level 1 is intended for pilot and early-stage trials that are exploratory, involve limited human exposure (often meaning smaller sample sizes), and are positioned to make meaningful progress toward clinical translation. For this level, preliminary data are encouraged but not mandatory, making it more accessible to teams that have a solid rationale and plan but may not yet have extensive clinical trial data. Funding Level 2 is intended for larger clinical trials with the potential to produce statistically robust, definitive results that support evidence-based practice and could drive changes in clinical practice. This level welcomes larger-scale pragmatic studies, randomized controlled trials, and comparative effectiveness trials, but it requires preliminary data relevant to the proposed trial, reflecting the expectation that Level 2 projects are more mature and ready for rigorous, large-sample testing.

Administratively, the opportunity was listed as a discretionary program under CFDA 12.420 and allows two primary funding instruments: grants and cooperative agreements. Eligibility is described as unrestricted, meaning it is broadly open to many entity types unless further limited by the full announcement text. The posting indicates an anticipated total of about four awards. The original opportunity was posted April 1, 2021, with an original closing date of July 29, 2021. The listing shows an award ceiling of 0, which typically signals that applicants must rely on the detailed funding restrictions in the full announcement rather than a single top-line maximum shown in the summary record.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Orthotics and Prosthetics Outcomes, Clinical Trial Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 01, 2021.
• Applicants must submit their applications by Jul 29, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 4 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 OPORP CTA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: